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INTRODUCTION
Multiple myeloma (MM) is the most common malignancy
of plasma cells and accounts for about 1% of all malignant
diseases and 10% of haematological malignancies (Lok-
horst et al., 2002). 60–100 MM cases are diagnosed in Lat-
via yearly (Pildava, 2012).
Strong CD56-positivity in plasma cells (PC) of some pa-
tients with MM, in contrast to normal plasma cells that are
mostly CD56-negative in others with MM, has been known
since the 1990. However, recent studies of CD56 expression
are contradictory. Aberrant CD56 expression has been dem-
onstrated in 70% to 80% of MM cases at diagnosis (Harada
et al., 1993; Harrington et al., 2009). Absence of CD56 ex-
pression in MM patients is associated with more aggressive
disease and shorter overall survival (Rawstron et al., 1999;
Hundemer et al., 2007; Sahara et al., 2009). Some studies
have demonstrated a correlation between CD56-negative
myeloma and bone lesions (Chang et al., 2006). Other
authors have not found a significant correlation between
CD56 expression and clinical parameters and overall sur-
vival (Dunphy et al., 2007).
Cyclin D1 is a product of the CCND1 gene and in associa-
tion with cyclin-dependent kinases controls proliferation of
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CD56, p53, and Cyclin D1 detection in plasma cells (PC) can help to predict prognosis of multiple
myeloma (MM). Clinical and biochemical prognostic parameters were analysed in a group of 122
patients with primary diagnosed MM in the period 2011–2015. Bone marrow biopsies were ana-
lysed with Cyclin D1, p53, CD56 antibodies. Statistical analysis was performed using Microsoft
Excel 2010 and Graph Pad Prism 5. Lack of CD56 expression and p53-positivity were signifi-
cantly correlated with a low glomerular filtration rate (GFR), low platelet count and haemoglobin
level, as well as with high serum creatinine levels. Patients with Cyclin D1 expression in PC had a
significantly higher serum calcium level and more common osteolytic lesion in bones. CD56-
negative as well as p53, Cyclin D1-positive groups had advanced Salmon–Durie MM stages by
and significantly higher ß2-microglobulin. Expression of p53, Cyclin D1 and lack of CD56 antigen
in PC are negative predictive factors in cases of MM, as these patients were diagnosed as having
late Salmon–Durie stage and higher ß2-microglobulin level. Expression of p53 and lack of CD56
antigen in PC is associated with an increased creatinine level in blood and decreased GFR;
therefore, these are criteria for chronic renal failure progression and poorer prognosis of MM.
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eukaryotic cells at specific points in G1, S, G2 phases.
(Hitomi et al., 1999; Alt et al., 2000; De Falco et al., 2004;
Padhi et al., 2013). Aberrant expression of Cyclin D1 in
MM is associated with genetic abnormalities like translo-
cation t (11;14)(q13;q32), polysomy for chromosome 11,
amplification of CCND1 and other genetic abnormalities;
this feature is associated with longer overall survival
(Hitomi et al., 1999; Cook et al., 2006; Padhi et al., 2013).
Immunohistochemically detected Cyclin D1 protein expres-
sion in myeloma cells has been reported in 24–50% cases;
some researchers consider that it might provide clinically
useful prognostic information (Markovic et al., 2004; Cook
et al., 2006; Padhi et al., 2013).
Athanasiou et al. described a correlation between Cyclin D1
overexpression in MM and higher histological grade with
favourable prognosis. These patients had a significantly
lower level of haemoglobin (Athanasiou et al., 2001). How-
ever, there are studies that have not demonstrated any corre-
lation between Cyclin D1 expression and clinical prognostic
parameters (Markovic et al., 2004; Dunphy et al., 2007;
Padhi et al., 2013).
p53 protein is a TP53 gene product, which has a crucial role
in cell death and can be observed when cells undergo
apoptosis in response to oncogenic stimuli. Normally, the
cell cycle of cells with damaged DNA is arrested at G1-S
checkpoint until the damage is repaired, but cells that lack
p53 or contain a mutant form are not arrested at G1. Loss or
mutation of TP53 is probably the most common single ge-
netic change in malignancies when cells do not undergo
apoptosis and so escape the control. Tumours that have not
lost TP53 very often have mutated versions of it (Strachan
et al., 1999; Soussi et al., 2010). MM patients with aberrant
p53 nuclear expression usually are diagnosed in advanced
clinical and histological stages, as well as have significantly
shorter overall survival than patients without this abnormal-
ity. del(17p13) (TP53) and p53 immunohistochemical ex-
pression are strongly correlated (Chang et al., 2007; Souss
et al., 2010; Chen et al., 2012).
Of course, overall survival of MM patients depends not
only on the stage of MM, but also on different methods of
chemotherapy (Soverini et al., 2003; Markovic et al., 2004;
Lonial et al., 2016) and concomitant diseases. Some clinical
and serological findings like osteolitic changes, glomerular
filtration rate (GFR), level of ß2-microglobulin, M-protein,
haemoglobin, calcium, albumin, creatinine etc. are useful
for detection of MM stage and prognosis (Sailer et al.,
1995; Goldschmidt, et al., 2001; Greipp et al., 2005). From
2005, the International Staging System for Multiple Mye-
loma has been used for MM staging, and the Salmon–Durie
clinical staging system has been applied accordingly for the
Classification of Multiple Myeloma (Greipp et al., 2005).
The aim of our study was to evaluate CD56, Cyclin D1, p53
expression in bone marrow tissue and its correlation with
clinical and biochemical prognostic parameters of MM
cases.
Our study is the first in European and Baltic countries that
is based on the analyses of 122 patients. We found statisti-
cal correlation between more than 10 clinical and biochemi-
cal markers and expression of CD 56, p53, and Cyclin D1 in
myeloma cells of bone morrow. These data will be used
as predictive indicators of progression of multiple mye-
loma.
MATERIALS AND METHODS
Study population. Bone marrow biopsies of 122 patients
from Rîga East Clinical University Hospital’s Haematology
Centre with MM diagnosed between 2011 and 2015 were
enrolled in the study. Our study was designed in conforma-
tion to the Helsinki Declaration. The study protocol was ap-
proved by the Committee of Ethics, Rîga Stradiòð Univer-
sity.
Immunohistochemistry. Bone marrow biopsies were fixed
in 10% neutral (pH = 7) buffered formalin solution, decalci-
fied in “MicroDecfast” decalcification solution (Diapath, It-
aly), processed in “Sakura Tissue-Tek VIP 5” vacuum infil-
tration tissue processor and embedded in paraffin. All bone
marrow biopsies were stained with routine haematoxylin
and eosin, Periodic acid-Schiff (PAS), Giemsa stain and
Gordon and Sweet's reticulin silver staining method using
standard protocols (Bio-optica, Italy).
Immunohistochemical antigen expression was determined
by a standard polymer based visualisation system (EnVision
method by Dako/Agilen, Denmark/U.S.A.).
4–5-µm thick formalin fixed paraffin-embedded bone mar-
row biopsies were placed on adhesive positively charged
slides. After de-waxing and rehydration, through alcohols to
water, the slides were incubated with 3% H202 for 10 min-
utes to inhibit endogenous peroxidase activity. The micro-
wave-based antigen retrieval was performed in a freshly
prepared 0.01 mol/l sodium citrate buffer (pH 6.0) solution
at 750 W for 3 cycles, 10 minutes each.
Samples were immunostained using primary antibodies:
Cyclin D1 (Clone-SP4, Ready-to-Use, Dako), p53 (Clone-
Do-7, Ready-to-Use, Dako) and CD56 (Clone-123C3, at a 1
: 50 dilution, Dako) and 3.3?-diaminobenzidine-tetrahydro-
chloride dihydrate (DAB) as the chromogen (DAKO, Den-
mark). Slides were counterstained with Mayer’s haematox-
ylin, dehydrated in alcohol, cleared in xylene and cover
slipped.
Cyclin D1, p53, and CD56 expression in cytoplasm of mye-
loma cells was considered positive if more than 10% cells
were stained with strong positive reaction, but considered
negative if less than 10% of the cells were stained. We eval-
uated correlation between histological findings and patients'
clinical data — gender, age, osteolytic lesion, laboratory
data and stage by Classification of Multiple Myeloma ac-
cording to the Salmon–Durie clinical staging system and the
International Staging System (Durie and Salmon, 1975;
Greipp et al., 2005) for MM.
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Surgery material of five patients with nonspecific spondyli-
tis was used as control. These samples were characterised as
having prominent polyclonal plasmocytosis without atypi-
cal changes.
All slides were examined and photographed with a Leica
Microscope (Leitz, Wetzlar, Germany).
Clinical-laboratory data. Normal levels of the studied
clinical-laboratory parameters are shown in brackets:
ß2-microglobulin (0–3 mg/l), albumin (34–52 g/l); haemo-
globin (male: 126–175 g/l female 118–161 g/l, platelet
count (150–410 × 10·9l), glomerular filtration rate-GFR (90
ml/min/1.73 m2), creatinine (male: 30–106 µmol/l, female:
30–80 µmol/l); calcium level (2.2–2.6 mmol/l), M-protein.
Statistical analysis. Statistical analysis was performed us-
ing Microsoft Excel 2010 and Graph Pad Prism 5 software.
The results were expressed as mean (M) ± standard devia-
tion (SD) or percentage and range. Normality was assessed
using the D’Agostino-Pearson omnibus normality test.
Correlation between histological, clinical and laboratory
parametric data were determined by Pearson's or Spear-
man's tests. The Student’s unpaired t-test or Mann-Whitney
U test was used for comparing results between groups; dif-
ferences were considered statistically significant at p < 0.05.
RESULTS
Distribution of the patients according to the Salmon–Durie
clinical staging system was: I – 20% (n = 24); II – 45% (n =
55), III – 35% (n = 43). The patient mean age was 65 ±
10.81 years (range 36–81). The male to female ratio was 1:
1.3. Mean bone marrow cellularity in the whole group was
57.87% ± 20.64% (range 15–95%). Mean percentage of
atypical plasma cells in BM biopsies was 52.14% ± 21.1%
(range 15–90).
CD56 antigen expression in plasma cells. CD56 positive
plasma cells (Fig. 1) were found in 95 (78%) cases. Signifi-
cant positive correlation (Table 1) was shown by the Spear-
man test between CD56-positive expression and glomerular
filtration rate, platelet count and haemoglobin level, but sig-
nificant negative correlation was observed between CD56
expression and ß2-microglobulin, serum creatinine levels
and Salmon–Durie clinical stage. Our results showed that
the patient group with CD56-negative plasma cells had a
significantly lower haemoglobin level, GFR (Fig. 2) and
also lower platelet count, in comparison to the CD56-
positive group. CD56-negative patients were predominately
at an advanced Salmon–Durie disease stage and had signifi-
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Fig. 1. Expression of CD56 antigen in a diffuse population of myeloma
cells, 100×.
T a b l e 1
CORRELATION OF CYCLIN D1, P53 AND CD56 EXPRESSION WITH CLINICAL AND LABORATORY DATA OF MULTIPLE MYELOMA PA-
TIENTS
CD56 Cyclin D1 p53
ß2-microglobulin, mg/dl negative significant correlation
(r = –0.22; p = 0.013)
positive significant correlation
(r = +0.19; p = 0.033)
positive significant correlation
(r = +0.27; p = 0.0025)
Albumin, g/l ns ns ns
Haemoglobin, g/dl positive significant correlation
(r = +0.25; p = 0.005)
ns negative significant correlation
(r = -0.38; p < 0.0001)
Thrombocyte count, 109/l positive significant correlation
(r = +0.2; p = 0.031)
ns negative significant correlation
(r = –0.21; p = 0.023)
GFR, ml/min positive significant correlation
( r = +0.43, p < 0.0001)
ns negative significant correlation
(r = –0.21; p = 0.021)
Creatinine, µmol/l negative significant correlation
(r = –0.43; p < 0.0001)
ns positive significant correlation
(r = +0.21; p = 0.018)
Osteolytic lesions, % ns positive significant correlation
(r = +0.29; p = 0.0014)
ns
Calcium, mmol/l ns positive significant correlation
(r = +0.24; p = 0.009)
ns
M-protein, g/l ns ns ns
Clinical stages by Salmon– Durie,
n and %
negative significant correlation
(r = –0.3; p = 0.0009)
positive significant correlation
(r = +0.28; p = 0.002)
positive significant correlation
(r = +0.41; p < 0.0001)
ns, not significant, p > 0.05)
GFR, glomerular filtration rate
cantly higher ß2-microglobulin and serum creatinine
(Fig. 2) levels, when compared to the CD56-positive group
(p < 0.05). Patient gender, age, the level of LDH, albumin,
CRP, calcium, and M-protein did not show any statistically
significant differences between CD56-positive and negative
groups (Table 2).
Cyclin D1 antigen expression in plasma cells. Cyclin D1
protein expression (Fig. 3) was detected in 62 (51%) cases.
Positive correlation (Table 1) was observed between cyclin
D1 expression and Salmon–Durie clinical stage, calcium,
ß2-microglobulin level and osteolytic lesion in bones (p <
0.05). The patient group with positive Cyclin D1 expression
in PCs (Table 3) had significantly higher ß2-microglobulin
(p = 0.034) and calcium (p = 0.0096) levels, compared to
those in the Cyclin D1 negative group (Fig. 4). The Cyclin
D1 positive patient group had a more advanced Salmon–
Durie stage and had significantly more pronounced bone
osteolitic lesions, compared these parameters for the Cyclin
D1 negative patient group (p < 0.05).
p53 antigen expression in plasma cells of MM patients.
p53 protein was detected in 44 (36%) cases (Fig. 5). Signifi-
cant positive correlation (p < 0.05) was observed between
p53 protein expression in plasma cells (Table 1) and
Salmon–Durie MM clinical stage, ß2-microglobulin and se-
rum creatinine level. Furthermore, significant negative cor-
Proc. Latvian Acad. Sci., Section B
Fig. 2. CD56 antigen positive and
negative groups: A) haemoglobin
level; B) ß2-microglobulin level;
C) creatinine level; D) glomerular
filtration rate.
Fig. 3. Cyclin D1 positive plasma cells, 100×.
Fig. 4. Cyclin D1 positive and nega-
tive groups: A) ß2-microglobulin
level; B) calcium level.
relation was observed between p53 expression and haemo-
globin level, glomerular filtration rate and thrombocyte
count. The p53-positive group (Table 4) had a more ad-
vanced Salmon–Durie MM stage (p < 0.0001), significantly
higher ß2-microglobulin (p = 0.029), serum creatinine (p =
0.0192) levels, compared these parameters in the
p53-negative group (Fig. 6).
The p53-positive group had a significantly lower haemoglo-
bin level (p < 0.0001) and platelet count (p = 0.0188) than
in the p53-negative group. In addition, the p53-positive
group had a lower GFR (Fig. 6), compared to that in the
p53-negative group (p = 0.0215).
DISCUSSION
Histological examination combined with immunohisto-
chemistry plays an important role in MM management. Be-
sides being the gold standard for diagnosis, it provides
prognostic information such as degree of bone marrow infil-
Proc. Latvian Acad. Sci., Section B
T a b l e 2













Male / Female ratio 14 / 13 39 / 56 ns
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Clinical stages by Salmon–Durie,
n and %
I / II / III
1 / 10 / 16
4% / 37% / 59%
I / II / III
23 / 45 / 27




IgG / IgA / Bence Jones /
non-secretory MM
n and %
18 / 3 / 4/ 2
67% / 11% / 15% / 7%
62 / 20 / 10 / 3
65% / 21% / 11% / 3
ns
* mean ± SD; 95%. CI, confidence interval; ns, not significant, p > 0.05
MM, multiple myeloma
Fig. 5. p53 intranuclear expression in myeloma cells, 200×.
tration, grade of tumour cell atypia and immunophenotype.
Experimental treatment based on immunohistochemical
findings was recently introduced for refractory MM, for ex-
ample, by stimulation of p53-related apoptosis and antibody
based treatment with anti-CD56 drugs (Soverini et al.,
2003; Teoh et al., 2014; Lonial et al., 2016). The current
tendency of individually tailored treatment implies that
in the future, the immunophenotype of each MM patient
will have to be taken into consideration, since genetic and
immunohistochemical characteristics are very heterogene-
ous.
In the current study, we retrospectively analysed prognostic
plasma cell antigenic biomarkers (Cyclin D1, CD56, p53) in
122 trephine bone marrow biopsies and evaluated their rela-
tion to serological, clinical and laboratory parameters in a
large cohort of primary MM patients.
Several markers, like ß2-microglobulin, haemoglobin, and
albumin levels have been proposed as prognostic factors in
MM. It is also known that overall survival of MM patients
is correlated with the creatinine level and GFR (Durie and
Salmon, 1975; Greipp et al., 1988; Hartmut et al., 2001;
Greipp et al., 2005). Since previous studies (Sailer et al.,
1995; Greipp et al., 2005; Lonial et al., 2016) demonstrated
prognostic significance of the immunohistochemically de-
tected phenotype of tumour cells in MM, new data on rela-
tions between biochemical and histological prognostic
markers could be of particular interest.
We detected an aberrant CD56 expression in myeloma cells
in 78% of cases, using immunohistochemical method. Ac-
cording to literature data, patients that are CD56-negative
(detected by flow cytometry) have poorer prognosis (Hague
et al., 1994; Korsrneyer et al., 1992). Our CD56-positive
Proc. Latvian Acad. Sci., Section B
T a b l e 3
CYCLIN D1 EXPRESSION ACCORDING TO CLINICAL AND LABORATORY DATA*
Cyclin D1 positive group
n = 62
Cyclin D1 negative group
n = 60
Statistical significance







Male / Female ratio 26 / 36 27 / 33 ns


































































I / II / III
6 / 28 / 28
10% / 45% / 45%
I / II / III
18 / 27 / 15




IgG / IgA / Bence Jones /
non-secretory MM
n and %
43 / 7 / 8 / 4
69% / 11% / 13% / 7%
37 / 16 / 6 / 1
62% / 26% / 10% / 2%
ns
* mean ± SD; 95%. CI, confidence interval; ns, not significant, p > 0.05
group presented at late Salmon–Durie clinical stage, with a
high ß2-microglobulin level, low haemoglobin level, low
platelet count and renal insufficiency and was thus was as-
sociated with clinical and laboratory markers of poorer
prognosis. Clinical follow-up with overall survival assess-
ment seems to be required to resolve the contradiction.
Cyclin D1 is another immunochistochemical prognostic
marker associated with genetic abnormalities. Cyclin D1 is
necessary for the coordination of the cell cycle G1 / S tran-
sition, as cyclins act as regulators of cyclin dependent kin-
ases and have a role in tumourogenesis. Some studies have
shown it to have positive prognostic value (Markovic et al.,
2004; Cook et al., 2006; Padhi et al., 2013). In our study we
detected Cyclin D1 protein expression in 51% of cases, and
it was associated with poorer prognostic indicators, like
high ß2-microglobulin and calcium levels. In our analysed
group of patients with Cyclin D1 overexpression there were
more osteolytic lesions.
p53 was detected in 36% of examined cases using the
immunohistochemical method. p53 overexpression was cor-
related with shorter overall survival. p53 plays a role in
apoptosis (Chang et al., 2007; Souss et al., 2010; Chen et
al., 2012). In our study, p53 expression in myeloma cells
within a group of patients was also correlated with many
prognostic clinical and laboratory findings, such as a high
ß2-microglobulin level, late stage according to the Salmon–
Durie classification, low haemoglobin level, platelet count
and renal insufficiency indicated by a decreased GFR and
elevated creatinine level.
We have found that overexpression of CD56, Cyclin D1
and p53 in myeloma plasma cells showed a statistically sig-
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T a b l e 4













Male / Female ratio 23 / 21 30 / 48 ns




































































I / II / III
2 / 16 / 26
5% / 36% / 59%
I / II / III
22 / 39 / 17




IgG / IgA / Bence Jones /
non-secretory MM
n and %
27 / 9 / 6/ 2
61% / 20% / 14% / 5%
53 / 14 / 8 / 3
68% / 18% / 10% / 4%
ns
* mean ± SD; 95%. CI, confidence interval; ns, not significant, p > 0.05
nificant correlation with various clinical and laboratory
characteristics of MM. Positivity for p53 and Cyclin D1 and
lack of CD56 antigen in myeloma plasma cells are negative
predictive factors in MM, associated with an advanced
Salmon–Durie stage and higher ß2-microglobulin levels.
Chronic renal failure progression, which was also associ-
ated with poorer prognosis in MM patients was related to
expression of p53 and lack of CD56 antigen in neoplastic
plasma cells, as in these patients there was an increased
creatinine level in blood and decreased GFR.
Many studies have evaluated Cyclin D1 as a factor of fa-
vourable prognosis and indicator of longer survival time in
patients treated with standard and new generation medicine.
There are studies about Cyclin D1 levels and it's correla-
tions with clinical and laboratory data. In our study, Cyclin
D1 overexpression was more typical for a graver Salmon–
Durie stage and higher ß2-microglobulin level, thus show-
ing progression of MM.
It is possible that patients with Cyclin D1 antigen expres-
sion in myeloma cells may have had improved responsive-
ness to chemotherapy treatment, which may explain the
higher survival rate in previously published studies (Marko-
vic et al., 2004; Cook et al., 2006; Padhi et al., 2013).
Statistical analysis of our study results showed that expres-
sion of Cyclin D1 was not correlated with the indicators of
renal function and that these patients did not develop
chronic renal failure, one of the most common complica-
tions of MM.
Thus, CD56, Cyclin D1 and p53 overexpression can be used
for making more precise morphological staging of MM and
can be applied as a predictive factor for indicating a more
aggressive therapy regimen.
CONCLUSIONS
1. Expression of p53 and Cyclin D1, but lack of CD56 anti-
gen in plasma cells, is a negative predictive factor in cases
of MM, as late Salmon–Durie stage and higher ß2-micro-
globulin level are more common in these cases.
2. Expression of p53 and lack of CD56 antigen is associated
with paraprotein hyperproduction in plasma cells, which in
turn damages renal parenchyma and affects renal function
and is associated with an increased creatinine level in blood
and decreased GFR.
These correlations are criteria for chronic renal failure pro-
gression and poorer prognosis of multiple myeloma pa-
tients.
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ANTIGÇNU P53, CIKLÎNA D1 UN CD56 EKSPRESIJA MIELOMAS ÐÛNÂS UN TO KORELÂCIJA AR SASLIMÐANAS
KLÎNISKAJIEM UN LABORATORISKAJIEM RÂDÎTÂJIEM PACIENTIEM AR MULTIPLU MIELOMU
Multiplas mielomas (MM) ðûnâs vairâku onkogçno un aberanto maríieru p53, ciklîna D1 un CD56 ekspresijai ir zinâma loma slimîbas
prognozçðanâ, lai gan daþkârt to nozîme literatûrâ tiek vçrtçta pretrunîgi. Pçtîjuma mçríis bija analizçt korelâciju starp p53, ciklîna D1 un
CD56 ekspresiju mielomas ðûnâs ar saslimðanas klîniskajiem un laboratoriskajiem râdîtâjiem. Tika izvçrtçti 122 slimnieku klîniski
laboratoriskie dati un kaulu smadzeòu biopsijâs imûnhistoíîmiski noteicâm p53, ciklîna D1 un CD56 ekspresiju. Statistiskâ analîze veikta ar
Microsoft Excel 2010 un Graph Pad Prism 5. CD56 antigçna iztrûkums mielomas ðûnâs, bet ar p53 ekspresija tajâs statistiski ticami
korelçja ar samazinâtu trombocîtu skaitu, kâ arî ar samazinâtu hemoglobîna lîmeni un paaugstinâtu kreatinîna lîmeni, bet ar pazeminâtu
glomerulu filtrâcijas âtrumu, kas liecina par nieru mazspçjas progresiju. Savukârt, ciklîna D1 ekspresija statistiski ticami bija saistîta ar
paaugstinâtu kalcija lîmeni serumâ un klîniski radioloìiskiem osteolîtiskiem kaulu bojâjumiem. MM slimniekiem ar CD56 antigçna
iztrûkumu, un ar p53 un ciklîna D1 ekspresiju statistiski ticamas bija vçlînâkas saslimðanas stadijas pçc Salmon–Durie klasifikâcijas un
attiecîgi augstâks ß2-mikroglobulîna lîmenis asinîs, kas norâda uz sliktâku prognozi saslimðanai.
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